Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Corneal Endothelial Dystrophy Market Growth in 2025?
The market size of corneal endothelial dystrophy has witnessed substantial growth lately. It is projected to escalate from $170.96 billion in 2024 to $185.38 billion in 2025, marking a compound annual growth rate (CAGR) of 8.4%. The growth recorded in the historic period can be credited to the surge in healthcare expenses, an increase in the occurrence of this particular type of corneal dystrophy, a rising aging population, the growing rate of eye diseases, and the rising prevalence of corneal disorders.
What Is the Forecast for the Corneal Endothelial Dystrophy Market Size Through 2029?
The market size of corneal endothelial dystrophy is predicted to undergo significant growth in the forthcoming years, reaching $252.88 billion by 2029 with a compound annual growth rate (CAGR) of 8.1%. This notable growth during the predicted period is ascribed to the escalation of corneal blindness in developing economies, augmented awareness concerning eye healthcare, the necessity for corneal transplants, advancements in healthcare facilities and an increased rate of chronic diseases. The forecast period also is expected to witness immense trends such as the progress in regenerative treatments, innovative upgrades in medical technology, developments in diagnostic methods, evolution in ophthalmic laser technology, and state-of-the-art technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp
What are the Key Market Players in Corneal Endothelial Dystrophy Market and How They’re Evolving?
Major companies operating in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L
What Are the Primary Growth Drivers in the Corneal Endothelial Dystrophy Market?
The upward trend in corneal transplant requirements is poised to fuel the advancement of the corneal endothelial dystrophy market. Corneal transplant is a medical operation aimed at substituting a worn-out or sickly cornea with a fit donor cornea to enhance vision and boost ocular wellbeing. The elevation in the demand for corneal transplants comes as a result of the growing occurrence of corneal ailments, the ongoing advancement in surgical methodologies, and better rates of organ donations. The treatment for corneal endothelial dystrophy includes a corneal transplant procedure, substituting the unhealthy endothelium with a healthy donor equivalent so as to restore the cornea’s transparency, decrease edema, and enhance vision. For instance, the year 2023 saw an increase by 2.7% in domestic keratoplasty (a type of corneal transplant) procedures in America according to the Eye Bank Association of America. The figure rose from 49,597 in 2022 to 50,925 in 2023. Consequently, the corneal endothelial dystrophy market is experiencing growth due to the surge in corneal transplant needs.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21158&type=smp
What Are the Leading Segments in the Global Corneal Endothelial Dystrophy Industry?
The corneal endothelial dystrophy market covered in this report is segmented –
1) By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps
2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy
3) By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Phototherapeutic Keratectomy: Excimer Laser Therapy, Corneal Reshaping
2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant, Cryopreserved Amniotic Membrane Transplant
3) By Anterior Stromal Puncture: Manual Technique, Laser-Assisted Technique
4) By Conjunctival Flaps: Partial Flap Technique, Full Flap Technique
What Are the Key Market Trends in the Corneal Endothelial Dystrophy Industry?
Significant players in the corneal endothelial dystrophy market are concentrating on the creation of novel treatments, such as allogeneic cell therapy, to meet unrealized health demands by providing innovative, less invasive treatment solutions that enhance patient results. Allogeneic cell therapy entails the usage of cells from a genetically distinctive donor of the same species to treat a recipient. Aurion Biotech Inc., a clinical-stage biotech firm from the United States for instance, launched Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy, a type of corneal endothelial disease, in September 2024. Aurion Biotech developed Vyznova (neltependocel), a cell therapy to treat bullous keratopathy, which impairs corneal endothelial cells resulting in vision issues. It is the first cell treatment approved in Japan for corneal endothelial disease. Vyznova involves corneal endothelial cells that are cultivated in a lab that can produce up to 1,000 doses from just a single donor. This groundbreaking treatment provides a non-invasive alternative to corneal transplantation, addressing the dearth of corneal donors and providing a novel method to recover vision for those afflicted with corneal diseases.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report
What Is the Regional Outlook for the Corneal Endothelial Dystrophy Market?
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21158
This Report Delivers Insight On:
1. How big is the corneal endothelial dystrophy market, and how is it changing globally?
2. Who are the major companies in the corneal endothelial dystrophy market, and how are they performing?
3. What are the key opportunities and risks in the corneal endothelial dystrophy market right now?
4. Which products or customer segments are growing the most in the corneal endothelial dystrophy market?
5. What factors are helping or slowing down the growth of the corneal endothelial dystrophy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model